Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Accretion PharmaceuticalsNSE:ACCPL -2.74%22 Debt-to-Equity is 0.23 as of Mar. 2026, which is 90% below its 10-year median of 2.20. GuruFocus rates NSE:ACCPL with a GF Score™ of 22/100. The stock has 6 warning signs investors should review. Among 811 Drug Manufacturers companies, Accretion Pharmaceuticals ranks better than 56.1% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Accretion Pharmaceuticals's Debt-to-Equity or its related term are showing as below:
NSE:ACCPL'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.23 Med: 2.2 Max: 2.52
Current: 0.23
During the past 5 years, the highest Debt-to-Equity Ratio of Accretion Pharmaceuticals was 2.52. The lowest was 0.23. And the median was 2.20.
NSE:ACCPL's Debt-to-Equity is ranked better than 56.1% of 811
companies
in the Drug Manufacturers industry
Industry Median: 0.28
vs NSE:ACCPL: 0.23
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Accretion Pharmaceuticals Debt-to-Equity Related Terms
Accretion Pharmaceuticals Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:ACCPL vs LLY, JNJ, ABBV: Debt-to-Equity Comparison
For the Drug Manufacturers - General subindustry, Accretion Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Accretion Pharmaceuticals Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Accretion Pharmaceuticals's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Accretion Pharmaceuticals's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accretion Pharmaceuticals (NSE:ACCPL) has a Debt-to-Equity of 0.23 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Accretion Pharmaceuticals and its competitors. This is 90% below median its historical median of 2.20. Over the past decade, Accretion Pharmaceuticals' Debt-to-Equity has ranged from 0.23 to 2.52. According to the industry distribution chart, Accretion Pharmaceuticals ranks #356 out of 811 companies in the Drug Manufacturers industry, placing it in the top 43.9%.
Is Accretion Pharmaceuticals' Debt-to-Equity too high?
Accretion Pharmaceuticals' current Debt-to-Equity of 0.23 is 90% below median its 10-year median of 2.20. Over the past 10 years, this metric has ranged from a low of 0.23 to a high of 2.52. The Drug Manufacturers industry median Debt-to-Equity is 0.28. Accretion Pharmaceuticals' value of 0.23 is 17.9% below this industry median. Based on the distribution chart, Accretion Pharmaceuticals ranks #356 out of 811 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Accretion Pharmaceuticals has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Accretion Pharmaceuticals' Debt-to-Equity compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Accretion Pharmaceuticals ranks #356 out of 811 companies for Debt-to-Equity. This puts Accretion Pharmaceuticals in the upper half of its industry. The industry median Debt-to-Equity is 0.28. Accretion Pharmaceuticals' value of 0.23 is 17.9% below this benchmark. Historically, Accretion Pharmaceuticals' own Debt-to-Equity has ranged from 0.23 to 2.52 over the past decade. While the company's 10-year median is 2.20 vs. the industry median of 0.28, Accretion Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Accretion Pharmaceuticals's current Debt-to-Equity of 0.23 is 17.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Accretion Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Accretion Pharmaceuticals's current Debt-to-Equity is 0.23, which is 90% below median its own 10-year median of 2.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accretion Pharmaceuticals stock overvalued right now?
Accretion Pharmaceuticals (NSE:ACCPL) has a current Debt-to-Equity of 0.23. The current Debt-to-Equity is 0.23, which is 90% below median its 10-year median of 2.20 and 17.9% below the Drug Manufacturers industry median of 0.28. Accretion Pharmaceuticals' overall GF Score™ is 22/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Accretion Pharmaceuticals (NSE:ACCPL), the current Debt-to-Equity is 0.23 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Accretion Pharmaceuticals Ltd is engaged in the manufacturing of Medicinal & Pharmaceutical Products. The company manufactures tablets, oral liquid, capsule, cream, ointment, mouthwash, dusting powder, gel, ear drops, lotion, shampoo, powder, syrup, among others.
22GF Score
Get the complete analysis for NSE:ACCPL
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ACCPL has been successfully added to your 
